Therapeutic Thursday: The ADC Gold Rush Has a Crowding Problem

Everyone in oncology BD is watching the ADC space this week, but most of the watching is backward-looking. The deals have already been done. The targets have already been claimed.

This edition is about what comes after that.

Last month, Daiichi Sankyo divested its consumer health unit to Suntory. That is not a story about OTC cold remedies. It is a story about a company that has decided, with unusual clarity, that it is now an ADC business and nothing else, targeting a position in the top five oncology companies within five years, built on five deruxtecan-payload drugs. The consumer divestment freed capital and management bandwidth.

The problem is that everyone else noticed. The TROP2 target alone now has Trodelvy, Datroway, and Merck/Kelun's sac-TMT competing for position, with fresh Phase III endometrial cancer data for sac-TMT landing last week.

Lilly quietly acquired CrossBridge, a preclinical-stage Houston biotech, specifically for its dual-payload TROP2 technology. GSK has five Phase III trials planned for its B7-H4 ADC, Mo-Rez. Roche in-licensed a B7H3 ADC from China's MediLink to rebuild SCLC optionality after a Daiichi program stumbled. Chinese biotechs presented multiple first-in-class multispecific ADC candidates at AACR this spring. The capacity to build an ADC is no longer the competitive advantage.

The question the whole field is now being forced to answer is: differentiation on what, exactly?

Enhertu remains the reference asset. Its DESTINY-Breast11 and DESTINY-Breast05 data at ESMO last October established it as the standard of care across multiple stages of HER2-positive breast cancer. What is contested is whether the HER2 model, one target, exceptional payload, iterative label expansion, was a repeatable formula or a specific convergence of biology, trial design, and first-mover timing that the rest of the field is now chasing.

The TROP2 space is the clearest test case. Trodelvy has TNBC and urothelial cancer approvals. Datroway posted an overall survival win in TNBC in October. Now sac-TMT has Phase III endometrial data analysts are reading as competitive with both. All three target the same receptor with broadly similar mechanisms. Commercial separation will come from label sequencing, payer contracting, and which combinations move first into earlier lines, not from the underlying biology.

CanWell's MMAE-exatecan HER2 ADC entering Phase I was designed explicitly to overcome Enhertu resistance. Lilly's CrossBridge acquisition was for a TROP2 drug with Topo1 and ATR payloads. Phrontline is engineering bispecific, dual-payload ADCs. Single-payload saturation is coming, and the next defensible position requires more complexity at the molecular level.

Whether that translates to better clinical outcomes, or just better patent positions, remains genuinely open.

Why You Should Care: If your pipeline includes a TROP2 or HER2 asset at Phase I, the clinical differentiation argument you are building today will land in a market where two or three approved drugs already own the front-line. The FDA will not do the commercial work for you. The indications where single-payload ADCs show efficacy are filling up faster than the label sequencing strategies to monetize them. The question to answer now, before the IND, is whether your payload and linker combination offers something prescribers cannot already get, not whether the drug works against the target.

GSK's deal with Halozyme for Enhanze subcutaneous delivery technology, announced earlier this month, was specifically for ADC administration. Enhanze enables subcutaneous injection of drugs typically given by IV infusion. GSK is not just thinking about whether Mo-Rez works across five Phase III trials. It is thinking about what it costs a hospital to administer IV versus subcutaneous, and how that affects formulary decisions when clinical differentiation between ADCs is narrow.

Administration burden does not appear in a clinical trial but matters enormously to payers and oncology centers managing throughput. That GSK is thinking about this before Mo-Rez has a Phase III readout suggests it has already concluded efficacy differentiation alone will not be sufficient.

Rigel's acquisition of Veppanu commercialization rights from Pfizer/Arvinas follows the same logic. Veppanu is the first approved PROTAC, not an ADC, but the commercial problem is identical: a novel mechanism drug in a crowded market with the commercial question entirely separate from the clinical one. Pfizer and Arvinas were never going to outcompete established oncology commercial teams on volume. Rigel can. The drug's fate was always going to be determined by who was selling it, not by what the Phase III showed.

Why You Should Care: GSK securing subcutaneous delivery before Mo-Rez has Phase III data is a signal about where the commercial fight in ADCs is heading. If you are building a commercial strategy for an ADC asset, the question of how the drug is administered is no longer downstream of approval. Payers and oncology centers are already thinking about it. An asset that requires 90-minute IV infusion in a crowded indication, competing against a drug that does not, has a structural disadvantage that the Phase III will not fix.

The camizestrant AdComm in May gave the field a useful data point about where FDA tolerance for novel trial design currently sits. AstraZeneca's "switch early" strategy, swapping a failing aromatase inhibitor the moment an ESR1 mutation appeared before visible tumor progression, was rejected as unproven. The committee called it "provocative but not paradigm-shifting."

As the field moves toward earlier line use, trial designs that rely on surrogate endpoints, novel switching strategies, or biomarker-gated entry criteria face a more skeptical FDA than the one that moved quickly on Enhertu's HER2-low approval. That approval was fast and consequential. It is not clear the same flexibility applies now.

The Adcetris untitled letter in April is a related signal. FDA flagged Pfizer's Facebook advertising for the lymphoma ADC as inadequately communicating indication and omitting risk information. In a class where dozens of new assets will need promotional frameworks built, regulatory complexity does not stop at approval.

Why You Should Care: The camizestrant rejection tells you something specific about the FDA you are filing with in 2026, not the one that approved Enhertu in 2022. If your ADC program is moving into earlier lines, where progression-free survival in a pre-treated population is no longer the endpoint bar, your trial design needs to be built around overall survival in a population the agency already recognizes. The flexibility the agency extended to HER2-low as a new clinical category was a specific moment. It is not a standing offer.

The volume of Chinese ADC assets, at AACR, in Phase I, in licensing conversations, is changing deal economics in ways that have not been priced into BD thinking. Two years ago, a Chinese biotech with a differentiated payload technology could expect competitive licensing interest from multiple Western companies. Today, every major oncology company either has an ADC program, a Chinese ADC partnership, or both. The leverage has shifted.

Alphamab, GlycoNex, Samsung Bioepis — each is trying to articulate why its approach is not simply another deruxtecan iteration. GlycoNex is going after targets that existing ADC linker chemistry cannot reach. Samsung Bioepis describes a "maturing" global market. These are not companies that think the opportunity is over. They are companies that know the terms of competition have changed.

The diligence question for BD teams is not whether the drug works in its initial indication. It is whether the target, payload, and linker combination offers something the acquirer's portfolio cannot already address. In a field where TROP2 has three mature competitors and HER2 is being contested by multiple Chinese challengers, "it works against the same target as Enhertu but with a different payload" is a harder commercial argument than it was in 2023. The deal that looks attractive at Phase I will face a much more crowded landscape by Phase III.

Why You Should Care: If you are in active diligence on a Chinese ADC asset, the leverage dynamic has shifted enough that the deal terms from 2023 are the wrong reference point. The Chinese companies that are still getting Western interest are the ones that cannot be replicated by what the buyer already has. GlycoNex and CanWell are positioning explicitly on that basis. If the asset you are evaluating hits TROP2 or HER2 with a DXd-adjacent payload, ask your counterpart what happens to the commercial argument when sac-TMT gets a US label. They will have an answer prepared. It may not survive contact with the actual filing.

Merck's pipeline disclosures through H2 2026 will clarify whether sac-TMT's endometrial data changes the Kelun acquisition calculus. If global Phase III data hold, the licensing structure becomes harder to defend against a buyout conversation. Watch for any language shift in Merck's investor materials on the partnership

The ADC field is not in trouble. It is in the phase every modality goes through after the first wave of genuine breakthroughs: the phase where the easy differentiation is gone and the hard work begins. Enhertu proved what an ADC could do. What the next five years will prove is whether anyone else can build the clinical, commercial, and regulatory case for a second one.

The companies that are asking the right questions now, about payload complexity, about administration, about what the FDA will actually accept in earlier lines, about whether a Chinese asset's Phase I profile survives contact with a crowded Phase III landscape, are the ones worth watching.

We will be back tomorrow with The Long View.